Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells

Diabetologia

Volumn 39, Issue 2, 1996, Pages 149-160

  Gugliucci, A ^a   Bendayan, M ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Clearance; Colloidal gold cytochemistry; Diabetes mellitus; Glomerulosclerosis; Glycation; LDL

Indexed keywords

BOVINE SERUM ALBUMIN; PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE SEVERITY; GLOMERULOSCLEROSIS; GLYCATION; IMMUNOCYTOCHEMISTRY; KIDNEY PROXIMAL TUBULE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE LEVEL; ULTRASTRUCTURE;

ANIMALS; BASEMENT MEMBRANE; GLOMERULAR MESANGIUM; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY TUBULES, PROXIMAL; LIPOPROTEINS, LDL; MALE; MICROSCOPY, IMMUNOELECTRON; NEPHRONS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE; SUBCELLULAR FRACTIONS;

EID: 0030031177     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00403957     Document Type: Article

References (60)

1. Nathan D (1994) Relation between metabolic control and long-term complications of diabetes. In: Kahn CR (ed) Joslin's Diabetes Lea and Febiger, Philadelphia
2. Dahl-Jorgensen K, Brinchmann-Hansen O, Bangstad HJ, Hanssen KF (1994) Blood glucose control and microvascular complications - what do we do now? Diabetologia 37: 1172-1177
3. The Diabetes Control and Complications Trial Data Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329: 977-986
4. Monnier VM, Cerami A (1981) Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211: 491-494
5. Brownlee M, Cerami A (1981) The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 50: 385-432
6. Brownlee M (1994) Glycation and diabetic complications. Diabetes 43: 836-841
7. Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138-151
8. Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23: 1-19
9. Brownlee M, Vlassara H, Cerami A. (1987) The pathogenetic role of nonenzymatic glycosylation in diabetic complications. In: MJC Crabbe (ed) Diabetic complications: scientific and clinical aspects. Churchill Livingston, London p94
10. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321
11. Brownlee M (1990) Advanced products of non-enzymatic glycosylation and the pathogenesis of diabetic complications. In: Rifkin H, Porte D Jr (eds) Diabetes mellitus: theory and practice. Elsevier, New York, pp 279-291
12. Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87: 432-438
13. Bucala R, Model P, Cerami A (1984) Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 81: 105-109
14. Bucala R, Vlassara H, Cerami A (1992) Advanced glycosylation end-products. In: Harding JJ Crabbe, MJC (ed) Posttranslational modifications of proteins, vol 2. CRC Press Inc, Boca Raton, pp 53-179
15. Makita Z, Bucala R, Rayfield EJ et al. (1994) Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet 343: 1519-1522
16. Vlassara H, Fuh H, Makita Z, Krungkrai, Cerami A, Bucala R (1992) Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89: 12043-12047
17. Makita Z, Vlassara H, Rayfield E et al. (1992) Hemoglobin- AGE: a circulating marker for advanced glycosylation. Science 258: 651-653
18. Makita Z, Radoff S, Rayfield EJ et al. (1991) Advanced glycosylation end products in patients with diabetic nephropathy. New Engl J Med 325: 836-842
19. Schmidt AM, Mora R, Cao K et al. (1994) The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 269: 9882-9888
20. Schmidt AM, Vianna M, Gerlach J et al. (1992) Isolation and characterization of two binding proteins for advanced glycation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267: 14987-14997
21. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosclerosis and Thrombosis 14: 1521-1528
22. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor specific increase in extracellular matrix production in mouse mesangial cells by advanced glycation end products is mediated via platelet derived growth factor. Proc Natl Acad Sci USA 89: 2873-2877
23. Horii Y, Skolnik E, Suthanthiran M, Vlassara H (1992) Novel T-cell receptors for advanced glycation endproducts (AGE) mediate production of IFN. Diabetes 41: 59A (Abstract)
24. Neper M, Schmidt AM, Brett J et al. (1992) Cloning and expression of RAGE: a cell surface receptor for advanced glycation end products of proteins. J Biol Chem 267: 14998-15004
25. Vlassara H, Moldawer L, Chan B (1989) Macrophage/ monocyte receptor for nonenzymatically glycosylated proteins is up-regulated by cachectin/tumor necrosis factor. J Clin Invest 84: 1813-1820
26. Vlassara H, Brownlee M, Cerami A (1988) Specific macrophage receptor activity for advanced glycosylation endproducts inversely correlates with insulin levels in vivo. Diabetes 37: 456-461
27. Radoff S, Vlassara H, Cerami A (1988) Characterization of a solubilized cell surface binding protein on macrophages specific for protein modified nonenzymatically by advanced glycosylation endproducts. Arch Biochem Biophys 263: 418-423
28. Vlassara H, Brownlee M, Cerami A (1986) Novel macrophage receptor for glucose-modified protein is distinct from previously described scavenger receptors. J Exp Med 164: 1301-1309
29. Yan SD, Schmidt AM, Anderson GM et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897
30. Wautier JL, Wautier MP, Schmidt AM et al. (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91: 7742-7746
31. Bucala R, Makita Z, Vega G et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dislipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91: 9441-9445
32. Deppisch R, Nawroth P (1994) Toxicity of uraemia - does it come of AGE? Nephrol Dial Transplant 9: 1-2
33. Makita Z, Radoff S, Rayfield EJ, Yang, Z (1991) Clinical assessment and significance of advanced glycation in patients with diabetic nephropathy. New Engl J Med 325: 836-842
34. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP (1994) Immunological quantification of advanced glycation end products in the serum of patients on hemodialysis or CAPD. Kidney Int 46: 216-222
35. Mitsuhashi T, Nakayama H, Itch T et al. (1993) Immunochemical detection of advanced glycation end products in renal cortex from streptozotocin-induced diabetic rats. Diabetes 42: 826-833
36. Kobert SM, Makita Z, Firanek CA, Vlassara H (1993) Advanced glycation end products in continuous ambulatory peritoneal dialysis patients. A J Kidney Dis 22: 588-591
37. Horiuchi S, Araki N, Morino Y (1991) Immunochemical approach to characterize advanced glycation end products of the Maillard reaction: evidence for the presence of a common structure. J Biol Chem 266: 7329-7332
38. Gugliucci A, Bendayan M (1995) Reaction of advanced glycation products with renal tissue from normal and streptozotocin-induced diabetic rats. An ultrastructural study using colloidal gold cytochemistry. J Histochem Cytochem 43: 591-600
39. Vlassara H, Striker LJ, Teichberg S, Fun H, Ming LY, Steffes M (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91: 11704-11708
40. Sell DR, Monnier VM (1990) End-stage renal disease and diabetes catalyze the formation of a pentose-derived cross-link from aging human collagen. J Clin Invest 85(2):380-384
41. Fuh H, Yang D, Striker L, Striker G, Vlassara H (1992) In vivo AGE-peptide injection induces kidney enlargement and glomerular hypertrophy in rabbits: prevention by aminoguanidine. Diabetes 41 [Suppl]:9A (Abstract)
42. Njoroge FG, Sayre LM, Monnier VM (1987) Detection of D- glucose derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohyd Res 167: 211
43. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM (1989) Aging of proteins: immunological detection of a glucose derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 264: 3758-3764
44. Njoroge FG, Monnier VM (1989) The chemistry of the Maillard reaction under physiological conditions: a review. Prog Clin Biol Res 304: 85-91
45. Steinbrecher UP (1987) Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 262: 3603-3610
46. Laemmli UK (1970) Cleavage of stuctural proteins during assembly of the head of bacteriophage T4. Nature 227: 680-685
47. Bjerrum OJ, Schafer-Nielsen C (1986) In: Dun MJ (ed) Analytical electrophoresis. Chemie, Weinheim, p 315
48. Hammes BD (1981) An introduction to polyacrylamide gel electrophoresis. In: Hammes BD, Rickvvood D (eds) Gel electrophoresis of proteins: a practical approach. IRL Press Ltd, London, pp 1-19
49. Schumaker VN, Puppione D (1986) Sequential flotation ultracentrifugation. Methods Enzymol 128: 155-170
50. Forte TM, Nordhausen RW (1986) Electron microscopy of negatively stained lipoproteins. Methods Enzymol 128: 442-457
51. Nakayama H, Taneda S, Kuwajima S et al. (1989) Production and characterisation of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 162: 740-747
52. Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycation end products in vivo. J Biol Chem 267: 5133-5138
53. Harlow E, Lane D (1988) Immunization. In: Harlow E, Lane D (ed) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, New York, pp 53-137
54. Harlow E, Lane D (1988) Purification and storage of antibodies. In: Harlow E, Lane D (ed) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, New York, pp 283-318
55. Smith P, Krohn R, Hermanson G et al. (1985) Measurement of protein using bicinconinic acid. Anal Biochem 150: 76-85
56. Bendayan M (1984) Protein A-gold electron microscopic immunocytochemistry: methods, applications and limitations. J Elec Micros Tec 1: 243-270
57. Bendayan M, Gingras D, Charest P (1986) Distribution of endogenous albumin in the glomerular wall of streptozotocin-induced diabetic rats. Diabetologia 29: 868-875
58. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H (1991) Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 174: 931-939
59. Dobrian A, Simionescu M (1995) Irreversibly glycated albumin alters the physico-chemical characteristics of low density lipoproteins of normal and diabetic subjects. Biochim Biophys Acta 1270: 26-35
60. Takahashi M, Ohishi T, Aoshima H et al. (1993) The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia 36: 664-667